Drug Trial Radar · NCT05278832
A Study of QLS31905 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
104
Planned (sponsor's estimate)
Start
Oct 25, 2021
Primary completion
Dec 31, 2022
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.
Conditions
- Advanced Solid Tumors
Interventions
QLS31905Drug
QLS31905 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities(DLTs)Time frame: 2 years
- Maximum tolerated Dose(MTD)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.